combined with other pharmaceutical
active substances" (page 11 of the description).
Linagliptin (BI 1356), a particularly preferred DPP-4
inhibitor of the present application ... DEVANSHU JOSHI
Signing Date:21.07.2022
10:49:18
enriching the art. Further, Linagliptin is characterized
by unique pharmacokinetics, such as with nonlinear
profile (less than
offering for sale, selling, importing and/or exporting the
medicinal product, Linagliptin in any form whatsoever
including Linagliptin API, Linagliptin formulation,
.
"Linagliptin Tablet ... Linagliptin + Metformin
Hydrochloride Tablets" or any "generic version" thereof
or any product sold under the trade marks/brand names
"LINARES
offering for sale, selling, importing and/or exporting the
medicinal product, Linagliptin in any form whatsoever
including Linagliptin API, Linagliptin formulation,
.
"Linagliptin Tablet ... Linagliptin + Metformin
Hydrochloride Tablets" or any "generic version" thereof
or any product sold under the trade marks/brand names
"LINARES
offering for sale, selling, importing and/or exporting the
medicinal product, Linagliptin in any form whatsoever
including Linagliptin API, Linagliptin formulation,
.
"Linagliptin Tablet ... Linagliptin + Metformin
Hydrochloride Tablets" or any "generic version" thereof
or any product sold under the trade marks/brand names
"LINARES
offering for sale, selling, importing and/or exporting the
medicinal product, Linagliptin in any form whatsoever
including Linagliptin API, Linagliptin formulation,
.
"Linagliptin Tablet ... Linagliptin + Metformin
Hydrochloride Tablets" or any "generic version" thereof
or any product sold under the trade marks/brand names
"LINARES
using, offering for sale, selling, importing and/or exporting the
.
medicinal product Linagliptin in any from whatsoever including
Linagliptin API, Linagliptin formulation, "Linagliptin Tablet ... Linagliptin + Metformin Hydrochloride Tablets", or any
"generic version" thereof or any product sold under the trade
marks/brand names "LINAMAC
infringing product therein. As per learned
Senior Counsel, manufacturing of Linagliptin
5mg and Linagliptin Metformin by the defendant
No.1 and its marketing and sale ... applicant No.1. Defendants neither have any
Patent to manufacture Linagliptin 5mg nor they
have been granted any licence by applicant
years.
11. The plaintiffs claims that the medicinal products 'Linagliptin Tablet'
and 'Linagliptin + Metformin Hydrochloride Tablets', covered by the
subject patent ... favour.
16. Accordingly, the defendants are restrained from manufacturing
'Linagliptin' in any form whatsoever including 'Linagliptin API',
'Linagliptin' formulation
manufacturer of
::: Downloaded on - 03/08/2022 20:04:05 :::CIS
Linagliptin 5mg at Serial No. 31 (page-254 of the list of the
.
documents ... duly registered in its favour. As per learned
Senior Counsel, manufacturing of Linagliptin 5mg by the
defendant and its marketing and sale
infringing product
therein. As per learned Senior Counsel, manufacturing or
advertising of Linagliptin 5 mg. and Linagliptin + Metformin by
defendant and its marketing, sale ... applicant No.1. Defendant neither has
.
any Patent to manufacture Linagliptin nor it has been
granted any licence by applicant
